2013 International Meeting on the Molecular Biology of Hepatitis B Viruses

2013年乙型肝炎病毒分子生物学国际会议

• 批准号: 8526887
• 负责人: SHUPING TONG
• 金额: $ 1万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8526887
• 关键词: Animal Model; Antiviral Agents; Antiviral Therapy; Applications Grants; Area; Authorization documentation; Basic Science; Biochemistry; Biology; Cellular biology; Cessation of life; China; Chinese People; Chronic Hepatitis B; Cirrhosis; Collaborations; Communities; Complex; DNA biosynthesis; Development; Diabetes Mellitus; Digestive System Disorders; Disease; Doctor of Philosophy; Educational workshop; Equilibrium; Europe; Event; Family; Feedback; Fostering; Foundations; Fund Raising; Funding; Future; Genetic Transcription; Grant; Growth; HBV Genotype; Hepatitis B; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatitis Delta Virus; Home environment; Immune response; Immunology; Individual; Infection; Institutes; International; Investigation; Joints; Kidney Diseases; Lead; Life; Liver Failure; Minority; Molecular Biology; Morphogenesis; Mothers; National Institute of Allergy and Infectious Disease; Nature; Oral; Pathogenesis; Perinatal; Population; Postdoctoral Fellow; Primary carcinoma of the liver cells; Proteins; Public Health; Relative (related person); Research; Research Personnel; Rice; Schedule; Scientist; Senior Scientist; Series; Speech; Students; System; Time; Translations; Travel; Underrepresented Minority; United States National Institutes of Health; Universities; Vaccines; Viral; Virus; Virus Diseases; Virus Receptors; Work; carcinogenesis; cost; experience; graduate student; medical schools; meetings; mouse model; mutant; pathogen; posters; prophylactic; public health relevance; receptor; reconstitution; trafficking; transmission process; unpublished works; virology

DESCRIPTION (provided by applicant): This proposal is a request for funding to support the travel expenses for young scientists to attend the 2013 International Meeting on the Molecular Biology of Hepatitis B Viruses, scheduled for Oct. 20 - 23 at Shanghai Medical College, Fudan University, Shanghai, China. This meeting, which has been held consecutively since 1985, is the only forum that gathers the international community of researchers focusing on the hepatitis B virus (HBV) and the closely associated hepatitis delta virus (HDV). Approximately a quarter of the world's population has been infected by HBV, and 350 million remain chronically infected of which 15 million are co- infected with HDV. As a result, nearly a million people die annually from complications of chronic HBV infection including liver failure, cirrhosis, and hepatocellular carcinoma. Current antiviral therapies are costly and ineffective. New HBV infections continue to arise despite the prophylactic vaccine, due to both underutilization of the vaccine and difficulty n interrupting perinatal transmission from infected mothers. It is therefore imperative that basic research on HBV continues and latest progress in the field is discussed and disseminated in a timely manner. A unique feature of the 2013 meeting is that it will be held for the first time in China, home to one-third of chronic hepatitis B carriers worldwide. It is anticipated that the meeting will promote lively scientific exchange between Chinese researchers and experts from the outside world and lead to fruitful collaborations in the near future. Besides the 10 oral sessions and two poster sessions, the workshop for the 2013 meeting will debate how chronic HBV infection causes hepatocellular carcinoma and evaluate the impact of antiviral therapy. The keynote speech by William Mason, a respected leader in the HBV field, will summarize major accomplishments of the field and point out matters requiring further investigation. One such area is the nature of the HBV receptor and early events in HBV lifecycle. In this regard Dr. Charles Rice's keynote speech will highlight the recent progress in identifying receptors for hepatitis C virus (HCV) and reconstituting a mouse model of HCV infection. As in the past, great effort has been made to minimize the cost of the meeting. Since 2005, the Hepatitis B Foundation has made a strong commitment to support this meeting by providing a permanent home for the meeting and making its staff available for publicizing the meeting, especially to universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the NIH to help defray the meeting costs is requested.

描述（由申请人提供）：本提案是一项资助年轻科学家参加定于 10 月 20 日至 23 日在复旦大学上海医学院举行的 2013 年乙型肝炎病毒分子生物学国际会议的旅费请求大学，上海，中国。该会议自1985年以来连续举办，是唯一聚集国际研究人员关注乙型肝炎病毒（HBV）和密切相关的丁型肝炎病毒（HDV）研究人员的论坛。世界上大约四分之一的人口感染了乙型肝炎病毒，3.5 亿人仍处于慢性感染状态，其中 1500 万人同时感染丁型肝炎病毒。因此，每年有近一百万人死于慢性乙型肝炎病毒感染的并发症，包括肝功能衰竭、肝硬化和肝细胞癌。目前的抗病毒疗法成本高昂且无效。尽管有预防性疫苗，但由于疫苗利用不足以及难以阻断受感染母亲的围产期传播，新的乙型肝炎病毒感染仍在继续出现。因此，继续开展乙型肝炎的基础研究并及时讨论和传播该领域的最新进展势在必行。 2013年会议的一个独特之处在于，它将首次在中国举行，中国拥有全球三分之一的慢性乙型肝炎携带者。预计此次会议将促进中国研究人员与外界专家之间的活跃科学交流，并在不久的将来促成富有成效的合作。除了 10 场口头会议和 2 场墙报会议外，2013 年会议的研讨会还将讨论慢性 HBV 感染如何导致肝细胞癌，并评估抗病毒治疗的影响。乙肝领域备受尊敬的领导者William Mason的主题演讲将总结该领域的主要成就，并指出需要进一步研究的问题。其中一个领域是 HBV 受体的性质和 HBV 生命周期的早期事件。在这方面，查尔斯·赖斯博士的主题演讲将重点介绍在识别丙型肝炎病毒（HCV）受体和重建HCV感染小鼠模型方面的最新进展。与过去一样，我们付出了巨大的努力来尽量减少会议的成本。自 2005 年以来，乙型肝炎基金会坚定承诺支持这次会议，为会议提供永久举办地，并让其工作人员能够宣传会议，特别是向拥有大量代表性不足的少数族裔的大学宣传会议。为了让初级和少数族裔研究人员参与，NIH 提供支持以帮助支付会议费用 要求费用。